结核病治疗试验中妊娠暴露结局分析
本研究分析了一项结核病治疗3期临床试验中妊娠妇女的结局。740名女性中97人(13.1%)妊娠,共102次妊娠,其中30人暴露于研究药物。暴露于利福喷汀/莫西沙星短程方案的妊娠未观察到胎儿丢失或先天异常率升高。
要点
- 740名女性中13.1%妊娠,共102次妊娠。
- 30名 participants 暴露于研究药物,各组胎儿丢失率未见明显升高。
- 利福喷汀/莫西沙星短程方案未增加不良妊娠结局。
核心结论
- 在接受利福喷汀/莫西沙星短程方案治疗的结核病女性中,妊娠后未观察到胎儿丢失或先天异常率升高。
研究设计与样本
- 对一项3期临床试验中妊娠女性的事后分析,740名女性中97人(13.1%)妊娠,共102次妊娠。
主要发现
- 30名参与者(29.4%)暴露于研究药物。
- 胎儿丢失:对照组3/13(23.1%),利福喷汀/莫西沙星组1/9(11.1%),利福喷汀组1/8(12.5%)。
- 暴露妊娠中21例活产(每组7例),利福喷汀组1例婴儿报告先天异常。
临床怎么用
- 对于使用利福喷汀/莫西沙星短程方案的结核病女性,妊娠期间未观察到胎儿丢失或先天异常率升高,可为临床咨询提供参考。
局限性
- 暴露于研究药物的妊娠样本量小(30人),各组活产数少(每组7例),结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A previous study demonstrated noninferior efficacy of 4-month rifapentine/moxifloxacin regimen for tuberculosis (TB) treatment compared with the standard regimen. We analyzed pregnancy outcomes of women who became pregnant during the study. Among 740 women, 97 (13.1%) became pregnant. Of 102 pregnancies (in 97 participants), 30 (29.4%) participants were exposed to study drugs. Fetal loss was reported for 3/13 (23.1%) in the control regimen, 1/9 (11.1%) in the rifapentine/moxifloxacin regimen, and 1/8 (12.5%) in the rifapentine regimen. Among 21 live births in exposed pregnancies (7 in each arm), 1 infant with a congenital anomaly was reported in a participant on the rifapentine regimen. Among women receiving a short rifapentine/moxifloxacin regimen for tuberculosis who became pregnant, we observed no elevated rates of fetal losses or congenital anomalies.
引用
- Kurbatova EV, Whitworth WC, Bryant KE, et al. Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020. Emerg Infect Dis. 2025. PMID: 41490808. doi:10.3201/eid3112.250492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。